Cara Therapeutics (NASDAQ: CARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Cara Therapeutics and Brainstorm Cell Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cara Therapeutics $911,000.00 499.62 -$64.69 million ($2.33) -6.00
Brainstorm Cell Therapeutics N/A N/A -$5.06 million ($0.28) -14.23

Brainstorm Cell Therapeutics has higher revenue, but lower earnings than Cara Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

61.1% of Cara Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Brainstorm Cell Therapeutics shares are held by institutional investors. 7.7% of Cara Therapeutics shares are held by company insiders. Comparatively, 24.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cara Therapeutics and Brainstorm Cell Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Therapeutics 0 2 9 0 2.82
Brainstorm Cell Therapeutics 0 0 1 0 3.00

Cara Therapeutics currently has a consensus price target of $26.58, indicating a potential upside of 90.29%. Brainstorm Cell Therapeutics has a consensus price target of $9.00, indicating a potential upside of 125.82%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Cara Therapeutics.

Volatility & Risk

Cara Therapeutics has a beta of 3.08, suggesting that its share price is 208% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Profitability

This table compares Cara Therapeutics and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cara Therapeutics N/A -99.64% -85.20%
Brainstorm Cell Therapeutics N/A -56.24% -51.18%

Summary

Brainstorm Cell Therapeutics beats Cara Therapeutics on 7 of the 11 factors compared between the two stocks.

About Cara Therapeutics

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.